Yes, Dr. Michael Henderson serves as the Chief Executive Officer and Director of Apogee Therapeutics, successfully guiding the biotechnology enterprise through its foundational research phases, initial public offering, clinical trials, and the subsequent high-profile acquisition agreement with AbbVie.